Recent Updates
Recently added Catalysts
PRTA

Prothena to Report First Quarter 2019 Financial Results on May 7

Tuesday, April 30, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets. Consistent with past pra

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
8.1%
average across 2 past catalysts
Cash runway
~34 mo
Minimal dilution risk
Lead asset
PRX003
Phase 1 · Psoriasis

Full Press Release Details

DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 7.
Media & Investor Contact:
ShareAdd on Google
Tags: PRTA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 30, 2019

Biotech snapshot

Cash runway
$288M liquidity · $8M/mo burn
~34 mo
Minimal dilution risk
Lead asset
PRX003Phase 1
Psoriasis →

Catalyst track record

+34%
best trade around PRTA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for PRTA.

See every catalyst's timing & PoA →